Study on Trastuzumab Deruxtecan for People with Non-Small Cell Lung Cancer

Inclusion Criteria

• Must be 18 years or older.
• Able to follow the study procedures.
• Have a confirmed diagnosis of non-small cell lung cancer (NSCLC) at specific stages (II, IIIA, or selected IIIB).
• Have a HER2 mutation or amplification confirmed by recent lab tests.
• Have measurable disease as defined by medical criteria.
• Tumors must appear solid or subsolid on a CT scan.
• Must be evaluated by a surgeon to confirm that the cancer can be completely removed and that the patient is fit for surgery.
• Have adequate lung function for surgery.
• Have a heart function test showing a left ventricular ejection fraction (LVEF) of 50% or higher.
• Have an ECOG performance status of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Have adequate blood and organ function based on specific lab tests.
• Agree to use effective contraception during the study and for at least 4.5 months after the last dose of the study drug.
• Male participants must not donate sperm during the study and for at least 4.5 months after the last dose.
• Female participants must not donate eggs during the study and for at least 7 months after the last dose.
• Willing to attend all study visits and follow procedures.

Exclusion Criteria

• Have NSCLC that has invaded certain organs or is at a more advanced stage.
• Require a total lung removal to achieve complete cancer removal.
• Have had any previous treatment for lung cancer within the last 3 years.
• Have a history of certain lung diseases or conditions that affect lung function.
• Have active infections or immune system disorders.
• Have a history of severe allergic reactions to similar treatments.
• Have had major surgery within the last 28 days.
• Have other cancers within the last 3 years, except for certain low-risk cancers.
• Have heart conditions or other medical issues that could increase risks during the study.
• Be pregnant or breastfeeding, or planning to become pregnant during the study.